Datopotamab Deruxtecan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 153 publications
Treatment-Related Toxicities of Antibody-Drug Conjugates in Breast Cancer: A Bayesian Network Meta-Analysis.
Journal: Cancer control : journal of the Moffitt Cancer Center
Published: August 20, 2026
Antibody-drug conjugates in breast cancer: the first-line and curative setting.
Journal: Current opinion in oncology
Published: August 14, 2026
Real-world outcomes of datopotamab deruxtecan after trastuzumab deruxtecan in hormone receptor-positive, HER2-negative metastatic breast cancer.
Journal: Breast cancer (Tokyo, Japan)
Published: July 02, 2026
Pharmacological properties and clinical trial results of datopotamab deruxtecan (Dato-DXd, Datroway®)
Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica
Published: July 01, 2026
Evaluating datopotamab deruxtecan (Dato-DXd) as a novel treatment option for EGFR-mutated non-small cell lung cancer.
Journal: Future oncology (London, England)
Published: June 25, 2026
A Response to the Letter to the Editor: "Regarding "Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial".
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: June 09, 2026
Multi-target-directed drugs: new additions in 2025 and post-marketing safety surveillance of drugs marketed in 2022-2024.
Journal: Pharmacological reports : PR
Published: June 02, 2026
Antibody-drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer.
Journal: Breast (Edinburgh, Scotland)
Published: May 21, 2026
Evolving Treatment Paradigms in Hormone Receptor-Positive, Human Epidermal Growth Factor 2-Negative Metastatic Breast Cancer.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: May 19, 2026
TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.
Journal: Future oncology (London, England)
Published: May 16, 2026
ILD with datopotamab deruxtecan combinations: a warning signal we should not ignore.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: May 12, 2026
Last Updated: 09/26/2026